Clinical trial breakthroughs continue to propel psychedelic biotech shares skyward, even as companies navigate complex regulatory pathways and lingering legal questions around these once-taboo substances
Definium Therapeutics Inc (NASDAQ: DFTX) (FRA: MMQ0) saw its shares surge more than 50 per cent on the Nasdaq after it announced strong results from a key late-stage trial. Investors cheered the news on Jun. 22, pushing the stock sharply higher.
The company’s DT120 drug, an orally disintegrating tablet based on a carefully formulated version of LSD, targets adults with major depressive disorder. In the Phase 3 “Emerge” study, researchers gave 149 participants a single 100-microgram dose or a placebo. Those who took the drug reported far greater relief from depressive symptoms. On a standard depression rating scale, they showed an 8.1-point better improvement than the placebo group after six weeks, with effects appearing as early as week one and still strong at week 12.
Response and remission rates also rose considerably. Patients experienced mostly mild, short-lived side effects on the dosing day, with no serious safety issues or signs of increased suicidal thoughts.
“As a psychiatrist, what excites me most is not the stock market reaction,” commented an American healthcare professional on social media. “It’s the possibility that we are witnessing the beginning of a new treatment paradigm for millions suffering from depression worldwide.”
This success builds on Definium’s impressive run. The stock has climbed roughly 170 per cent year to date. Beyond the trial data, momentum also came from President Trump’s April executive order, which aims to speed up access to psychedelic mental health treatments that have proven to be impactful in clinical studies. Particularly for veterans and first responders.
Analysts praised the results as among the strongest ever seen in depression studies. Oppenheimer Holdings Inc‘s (NYSE: OPY) investment banking arm raised its price target on the stock to US$60 from US$40 while keeping an Outperform rating, citing the impressive efficacy and safety profile.
The market’s enthusiasm is also fueled by Definium’s own history. In early 2024, when the company was still known as MindMed, the FDA granted Breakthrough Therapy Designation to the same LSD-based drug for generalized anxiety disorder. This regulatory seal of approval sent the stock up more than 50 per cent at the time as well.
However, these milestones also underscore a persistent tension for the sector. Despite the Breakthrough designation, LSD remains a Schedule I substance under federal law, and while Definium operates legally under strict FDA protocols, the path to widespread commercialisation remains murky.
In other recent news, Definium played a key role in organising a policy forum in Washington, D.C., on May 19. Titled “Rethinking Psychedelic Treatment for America’s Mental Health Crisis,”, the event gathered lawmakers, researchers, advocates and veterans’ groups. Discussions focused on scientific progress, policy changes and ways to expand access for conditions such as depression and PTSD. Company representatives joined panels that underscored the need for collaboration between science, government and patient voices.
Definium team members also recently attended the American Society of Clinical Psychopharmacology’s Annual Meeting in Miami Beach. There, they shared insights on how artificial intelligence tools can accelerate and improve the development of new psychiatric medicines.
LSD just passed its biggest depression trial — one dose, lasting relief
Definium Therapeutics says its proprietary LSD outperformed placebo significantly at 6 weeks, with over a third of patients responding
New MK‑Ultra on the march?
Source: gizmodo
Video: Vox on YT… pic.twitter.com/UefeCdThMw
— Jack Straw (@JackStr42679640) June 23, 2026
Read more: Colorado psychedelic church moves out of basement into strip mall
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
